All News
CAR-T Cell Therapies Show Promise for Autoimmune Disease
Two pioneering studies presented at #ACR25 spotlight the potential of CAR-T cell therapies to transform treatment for SLE and other autoimmune diseases. These early findings suggest a new frontier in immune modulation and https://t.co/KdNWmVc4Qc
Dr. John Cush RheumNow ( View Tweet)
Meta analysis evaluating age specific incidence across multiple registries (n=882)
Incidence 9.3 for women & 1.4 for men per 100k person-years
1. Wider distribution than I would have guessed
2. Much less age-dependency for men
@RheumNow #ACR25 Abstr#29W06 https://t.co/46dNGBZ45V
Links:
Mike Putman EBRheum ( View Tweet)
Phase 1 study of CAR-Treg in difficult to treat RA
4/6 pts had 50% reduction in TJC/SJC, no CYC/fludrabine required & good prelim safety data
CAR-T remains exciting, but less of the "totally magical everyone cured" stuff we saw w/initial CAR-T reports
@RheumNow #ACR25 https://t.co/kjBIkLCYpF
Links:
Mike Putman EBRheum ( View Tweet)
"Achieving good control of joint disease activity is probably the key objective of treatment of patients with RA-ILD"
- Gregory McDermott (Epi Abstracts, #2662)
Totally agree with this! SARD guidelines recommendingn drugs with mediocre activity in RA was surprising
@RheumNow
Mike Putman EBRheum ( View Tweet)
Excited about this target trial emulation in RA-ILD
Compared to RTX, NO significant difference in hospitalization/transplant/death for JAK, ABA, IL6 or TNF
Trends toward ABA and JAK looking better than RTX
Need trials for sure, but I like this project a lot
@RheumNow #ACR25 https://t.co/FQcphRvyHK
Links:
Mike Putman EBRheum ( View Tweet)
In AxSpA, an 8-week personalized exercise program improved trunk strength (+14.1%), mobility (+14.9%), and cardiorespiratory fitness ( increased oxygen pulse, ventilatory efficiency, anaerobic threshold). BASDAI and chest expansion also improved. Supports tailored rehab based on https://t.co/jawosa2AJK
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#Ianalumab decreases disease activity in active #Sjögren's #disease
2 phase3 DB #RCT added to #SoC in primary #SjD
>90% #Ro+
+#ESSDAI in monthly sc dosing vs placebo,
Many 2ndary outcomes improved, safe
LB#24 #ACR25 @ACRheum @RheumNow
#ACRBest https://t.co/Z4ooUg7Nos
Links:
Janet Pope Janetbirdope ( View Tweet)
In a PsA cohort (n=1291), higher BMI was independently linked to lower odds of achieving MDA—especially in TNFi-treated patients. Impact was strongest in pain, skin, enthesitis, and PRO domains, not swollen joints. Each unit increase in BMI reduced MDA odds by 4–7%. Highlights https://t.co/TxO3HP51uk
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#2686 Using HR-pQCT, researchers tracked bone changes in RA & PsA. Seropositive RA showed worst bone density & microstructure, worsening with disease activity. TNFi, RTX & BARI improved MCP bone density, highlighting the impact of inflammation and treatment. @RheumNow #ACR25
Mrinalini Dey DrMiniDey ( View Tweet)
Will CAR-Treg Rx be helpful in active #refractory #rheumatoid #arthritis?
Early data n=6 treated w low dose (3 per arm), ongoing and doses will escalate
Improvemt in #clinical #disease #activity
less inflammation on #synovial #biopsies 3 pts
#LB23 #ACR25 @RheumNow @ACRheum https://t.co/PkhsvztVjx
Janet Pope Janetbirdope ( View Tweet)
GLP-1 RA vs DPP4i & risk of rheumatic disease: propensity score matched cohort study using TriNetX
🔹 Lower incidence of OA, RA & gout w/ GLP-1 RA
🔹 No significant differences for PsA, SSc, axSpA, or SLE
@RheumNow #ACR25 https://t.co/BIVw3ajrFZ
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
#2662
Using Medicare data to emulate real-world RA-ILD trials, investigators compared RTX vs ABA, TOC, JAKi & TNFi
No sig differences in mortality, resp, hospitalisation or lung transplant across groups, suggesting other b/tsDMARDs may be as safe as RTX for RAILD
@RheumNow #ACR25
Mrinalini Dey DrMiniDey ( View Tweet)
Abstract 2694: Neutrophil:Lymphocyte ratio (NLR)- a practical step towards clinical monitoring of interferon?
Log₂NLR significantly correlated with all three IFN signatures across patients with SLE, systemic sclerosis, rheumatoid arthritis, and myositis
@RheumNow #ACR25 https://t.co/ujaOQGvAUV
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
#Deucravacitinib #Tyk2i in active #PsA to 52weeks
#PBO was crossed over at 16weeks
Ongoing improvement for high bar outcomes ex % in #minimal #disease #activity #MDA
#Xray #progression was reduced with real data (not imputed)
#ACR2025 @RheumNow @ACRheum https://t.co/kAMym2x8HQ
Links:
Janet Pope Janetbirdope ( View Tweet)
Abstract 2687: GLP-1 RA in PsA
In combined Toronto + NYU cohort, GLP-1 RA significantly associated with reduced:
- Weight, CRP, and pain scores
- Each 1% reduction in body weight associated w/ TJC, DAPSA, EQ-5D (QoL), LDL, Systolic BP
@RheumNow #ACR25 https://t.co/30lPDkALKs
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
McDermott et al. Target trial emulation of different b/tsDMARDs in RA-ILD. RTX as SOC. No significant differences seen in hospitalisation or death. Trends to abatacept and JAKi looking better... @RheumNow #ACR25 Abstr#2662 #ACRBest https://t.co/ghHEKztvgz
Richard Conway RichardPAConway ( View Tweet)
#PD1 Ab looks good and safe in active RA
Rosnilimab, a Selective and Potent Depleter of Pathogenic T
Many failed several Rx already
No safety signals compared to another PD1i
Proof of benefit in biospecimens too!
abst#LB19 #ACR25 @RheumNow @ACRheum
#ACRBest https://t.co/TmEOCfuHZU
Links:
Janet Pope Janetbirdope ( View Tweet)
Biologic choice in PsA: consider factoring in obesity ⚖️
Abstract 2691: In a longitudinal cohort study, obesity associated with ↓ odds of achieving minimal disease activity (MDA) among pts on TNFi, but not with other DMARDs
@RheumNow #ACR25 https://t.co/p4KaH6HKYj
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
#2661 In >5000 veterans with RA-ILD, 8 distinct FVC trajectories were identified. >1/2showed a progressive decline (≥0.7%/yr). These progressive patterns predicted higher mortality & respiratory hospitalisations, underscoring major disease heterogeneity. @RheumNow #ACR25
Mrinalini Dey DrMiniDey ( View Tweet)
